Alnylam Pharmaceuticals, Inc. vs Trump Media and Technology Group Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $225.68 (market cap $29.97B), while Trump Media and Technology Group Corp trades at $8.4 (market cap $2.30B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 13× Trump Media and Technology Group Corp's market cap. Which is the better fit depends on your goals.
| ALNY | DJT | |
|---|---|---|
Market Cap | $29.97B | $2.30B |
Sector | Health | Media |
52-Week High | $491.22 | $18.50 |
52-Week Low | $205.48 | $7.06 |
Enterprise Value | $27.93B | $2.37B |
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
DJT stock trades at $8.27, down 11.93% in the last session, reflecting bearish technical signals and fundamental challenges. The company reported Q2 2026 revenue of $1.67 million with a net loss of $238.1 million, driven by digital asset declines. Technical indicators show strong bearish momentum with support at $8 and resistance at $9-10 levels.
Outlook remains challenging with unsustainable valuation metrics (P/S ratio of 547.62) and persistent cash burn. Investment opportunities are limited given negative profitability and high business execution risks. Key risks include continued losses, competitive pressures, and volatile digital asset holdings affecting financial results.
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →